Treatment of prostatic cancer: effects on serum lipoproteins and the cardiovascular system.
We studied 32 patients with prostatic cancer before, and after 1 and 6 months of treatment with orchiectomy, estramustine phosphate or conventional estrogens (polyestradiol phosphate plus ethinyl estradiol). Lipid metabolism was evaluated by lipoprotein analysis and the intravenous fat tolerance test. Effects on the cardiovascular system were studied by exercise electrocardiography, blood volume estimation and thoracic electrical impedance measurement, a sensitive method to detect early signs of fluid retention. Present treatment programs for prostatic cancer seem to result in effects on lipoprotein metabolism that probably are of minor importance for the development of atherosclerotic manifestations. Measurement of thoracic impedance may be of value to detect fluid retention in individual patients.
D000368:Aged; D001794:Blood Pressure; D001811:Blood Volume Determination; D002307:Cardiography, Impedance; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology*; D002369:Castration; D003131:Combined Modality Therapy; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005080:Exercise Test; D005217:Fat Emulsions, Intravenous; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000628:therapy*; D013997:Time Factors
D045166:Estradiol Congeners; D005217:Fat Emulsions, Intravenous; D008074:Lipoproteins; D004961:Estramustine; D004997:Ethinyl Estradiol; D004958:Estradiol; C008958:polyestradiol phosphate